Altimmune, INC Form 4 insider transactions

Wayne Pisano, a director at Altimmune, Inc., was granted stock options for 34,900 shares on September 26, 2024, exercisable over the following 12 months.

Director Philip Hodges acquired 34,900 stock options in Altimmune, Inc. on September 26, 2024, according to a Form 4 filing.

Director Mitchel Sayare reports the acquisition of stock options in Altimmune, Inc.

Director Klaus Schafer reports the acquisition of stock options in Altimmune, Inc.

Director John Gill acquired 34,900 stock options in Altimmune, Inc. on September 26, 2024, according to a Form 4 filing.

Director Diane Jorkasky reports the acquisition of stock options in Altimmune, Inc.

Catherine A. Sohn, a director at Altimmune, Inc., acquired 34,900 stock options on September 26, 2024, according to a Form 4 filing with the SEC.

David Drutz, a director at Altimmune, Inc., reported the acquisition and disposal of common stock and stock options on August 19, 2024, according to a Form 4 filing with the SEC.

Andrew Shutterly, Acting CFO of Altimmune, Inc., reports the acquisition of 1,259 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.41 per share.

Altimmune's Chief Scientific Officer, M. Scot Roberts, acquired 650 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.41 per share on July 31, 2024.

Raymond Jordt, Chief Business Officer of Altimmune, Inc., reports the acquisition of 917 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.41 per share.

Matthew Scott Harris, Chief Medical Officer of Altimmune, Inc., acquired 1,486 shares of common stock through the company's Employee Stock Purchase Plan at a price of $5.41 per share.